Investors of Hims & Hers Health, Inc. Urged to Act on Securities Fraud Claims

Hims & Hers Investors Alert: Take Action Now

Overview

On July 6, 2025, Edelson Lechtzin LLP, a top-tier class action law firm, announced an investigation into potential securities fraud involving Hims & Hers Health, Inc. (NYSE: HIMS). This comes as the firm aims to protect the interests of all investors who acquired stocks tied to the company’s announcement regarding a partnership with Novo Nordisk A/S on April 29, 2025. Investors are urged to consider their legal options before the impending deadline to become lead plaintiffs in a class action lawsuit, which is set for August 25, 2025.

What Went Wrong?

The complaint posits that Hims & Hers made several materially false and misleading statements while simultaneously omitting critical facts concerning its collaboration with Novo Nordisk during the period from April 29, 2025, to June 23, 2025. Specifically, the claims allege that the company engaged in deceptive practices when promoting Novo Nordisk's Wegovy® weight loss drug. Additionally, they are accused of creating a substantial risk for the termination of their partnership due to these practices, which could have serious implications on investor confidence and stock value.

On April 29, Hims & Hers proudly announced a long-term partnership with Novo Nordisk, focusing on a bundled offering of Wegovy® through their platform. However, on June 23, Novo Nordisk made the decision to terminate the partnership, stating that Hims & Hers failed to comply with legal standards governing the sale of compounded drugs and allegedly disseminated misleading marketing that jeopardized patient safety. This announcement led to a significant plummet in Hims & Hers stock, dropping by $22.24 per share, or 34.63%, closing at $41.98.

Investor Action Steps

Investors who believe they have incurred losses as a result of Hims & Hers' actions are prompted to take immediate steps. They can contact Edelson Lechtzin LLP to discuss their potential claims and whether they qualify for lead plaintiff status. By doing so, investors not only can seek to recover their losses but also play a pivotal role in holding the company accountable for its alleged misconduct.

It's crucial for affected shareholders to note the importance of timing; the deadline for moving the U.S. District Court for the Northern District of California to appoint a lead plaintiff is fast approaching. Immediate consultation with Edelson Lechtzin LLP is recommended for personalized legal guidance. Interested individuals can reach out via phone at 844-696-7492 ext. 1 or by email to get clarity on the next steps.

Background on Hims & Hers Health, Inc.

Founded with the goal of transforming healthcare accessibility, Hims & Hers Health, Inc. is a telehealth and online pharmacy company that operates primarily in the U.S. and the U.K., providing both prescription and over-the-counter medications. It has also ventured into mental health services, showcasing a commitment to personal care products offered directly to consumers. However, its recent controversies could put this mission at risk, affecting both the company's reputation and its investors.

Conclusion

The investigation brought forth by Edelson Lechtzin LLP into Hims & Hers Health marks a crucial moment for investors. As allegations of securities fraud surface and lead plaintiff deadlines loom, prompt action becomes essential. Investors should remain vigilant and utilize available resources to safeguard their interests as this situation develops.

For further information, visit Edelson Lechtzin's website or contact the firm directly.